Clene Inc

Clene Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate, CNM-Au8, is being studied in multiple clinical trials, including a completed Phase 2 platform trial in amyotrophic lateral sclerosis (ALS), a completed Phase 2 proof-of-concept trial in early symptomatic ALS, two completed open-label investigator-blinded Phase 2 trials on brain energy metabolites, a completed Phase 2 trial for visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing multiple sclerosis, and a second Phase 2 trial in Parkinson's disease. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions for infectious diseases and wound healing, and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent for infection treatment and immune support. It markets dietary supplements including rMetx, an aqueous zinc-silver ion supplement, and KHC46, an aqueous gold supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.